3,168 reports of this reaction
5.7% of all DASATINIB reports
#1 most reported adverse reaction
PLEURAL EFFUSION is the #1 most commonly reported adverse reaction for DASATINIB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 3,168 FDA adverse event reports linking DASATINIB to PLEURAL EFFUSION. This represents approximately 5.7% of all 55,495 adverse event reports for this drug.
Patients taking DASATINIB who experience pleural effusion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PLEURAL EFFUSION is moderately reported among DASATINIB users, representing a notable but not dominant share of adverse events.
In addition to pleural effusion, the following adverse reactions have been reported for DASATINIB:
The following drugs have also been linked to pleural effusion in FDA adverse event reports:
PLEURAL EFFUSION has been reported as an adverse event in 3,168 FDA reports for DASATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PLEURAL EFFUSION accounts for approximately 5.7% of all adverse event reports for DASATINIB, making it one of the most commonly reported side effect.
If you experience pleural effusion while taking DASATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.